KRTX - AbbVie - Cerevel M&A deal lifts Reviva Karuna
2023-12-07 08:47:08 ET
More on Karuna, Reviva, etc.
- Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine
- Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript
- Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started
- FDA accepts Karuna Therapeutics schizophrenia drug for review
- Karuna reports positive safety data for schizophrenia drug KarXT
For further details see:
AbbVie – Cerevel M&A deal lifts Reviva, Karuna